The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …

Chemotherapy remains a powerful tool to eliminate malignant cells. However, the efficacy of
chemotherapy is compromised by the frequent emergence of intrinsic and acquired …

With nearly 10 million deaths, cancer is the leading cause of mortality worldwide. Along with
major key parameters that control cancer treatment management, such as diagnosis …

The tumour suppressor TP53 is a master regulator of several cellular processes that
collectively suppress tumorigenesis. The TP53 gene is mutated in~ 50% of human cancers …

Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …

Simple Summary Internationally, in women, breast cancer (BC) is the most common cancer
type and is the leading cause of cancer-related death. There are two main histological …

Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to
numerous structurally and functionally different chemotherapeutic agents. MDR is …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Mitochondria, the cell's major energy producers, also act as signaling hubs, interacting with
other organelles both directly and indirectly. Despite having its own circular genome, the …

Drug resistance remains a major hurdle to successful cancer treatment, being accountable
for approximately 90% of cancer-related deaths. In the past years, increasing attention has …